|Articles|April 8, 2008
India Converts Failing Vaccine Plants to Testing Labs
The Indian government has reacted to the enforced closure of three of its oldest vaccine manufacturing plants by launching a plan to convert them to drug testing laboratories.
Advertisement
INDIA-April 8. 2008-Nick Taylor reports for LabTechnologist.com that the BCG Vaccine Laboratory, Pasteur Institute of India and the Central Research Institute were shut down in January after failing to comply with current good manufacturing practices (cGMP). However, they will now receive a new lease of life testing the safety and efficacy of drugs and vaccines produced and sold within the country or exported. In addition to this they will be responsible for detecting counterfeit and spurious batches of drugs. To read more, click here: www.labtechnologist.com//news/ng.asp?n=84492&c=8YMEJy20NE7MmUMHbx1tWw%3D%3D .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
2
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
3
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
4
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
5